CYTOMX THERAPEUTICS INC's ticker is CTMX and the CUSIP is 23284F105. A total of 110 filers reported holding CYTOMX THERAPEUTICS INC in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $200,220,000 | -52.8% | 30,568 | -52.1% | 0.14% | -48.6% |
| Q3 2020 | $424,403,000 | -42.0% | 63,820 | -27.4% | 0.28% | -63.1% |
| Q2 2020 | $732,007,000 | +8.6% | 87,876 | 0.0% | 0.75% | -42.7% |
| Q1 2020 | $674,009,000 | -7.7% | 87,876 | 0.0% | 1.32% | +46.6% |
| Q4 2019 | $730,250,000 | +83.0% | 87,876 | +62.5% | 0.90% | +193.1% |
| Q3 2019 | $399,000,000 | -66.8% | 54,065 | -49.5% | 0.31% | -42.6% |
| Q2 2019 | $1,200,540,000 | +11.7% | 107,000 | +7.0% | 0.53% | +1.9% |
| Q1 2019 | $1,075,000,000 | +42.4% | 100,000 | +100.0% | 0.52% | +18.1% |
| Q4 2018 | $755,000,000 | +46.3% | 50,000 | +79.2% | 0.44% | +173.5% |
| Q3 2018 | $516,150,000 | +1.7% | 27,900 | +25.7% | 0.16% | -26.4% |
| Q2 2018 | $507,492,000 | -0.9% | 22,200 | +23.3% | 0.22% | +42.9% |
| Q1 2018 | $512,100,000 | +169.5% | 18,000 | +100.0% | 0.15% | +161.0% |
| Q4 2017 | $189,990,000 | – | 9,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 1,500,000 | $7,635,000 | 1.78% |
| Altium Capital Management LP | 1,233,642 | $6,279,000 | 1.65% |
| RA Capital Management | 3,500,000 | $17,815,000 | 0.25% |
| Soleus Capital Management, L.P. | 261,050 | $1,329,000 | 0.21% |
| Affinity Asset Advisors, LLC | 125,000 | $636,000 | 0.16% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,078,103 | $5,488,000 | 0.16% |
| Point72 Asset Management, L.P. | 6,303,025 | $32,082,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 249,146 | $1,268,000 | 0.13% |
| Candriam S.C.A. | 3,305,940 | $16,826,000 | 0.11% |
| RTW INVESTMENTS, LP | 1,400,939 | $7,131,000 | 0.11% |